Navigation Links
MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Date:3/4/2008

-

Depreciation and amortization 4,460,069 3,919,267

Warrant expense 2,100,000 -

Stock-based compensation 1,931,439 3,404,063

Deferred rent and credit on lease

concession (75,060) (15,957)

Amortization of premium on

marketable securities (39,687) 204,525

(Gain) or loss on disposal of fixed

assets - 23,185

Advance payment for sale of Keflex - (1,000,000)

Changes in:

Accounts receivable (384,273) 574,751

Inventories 1,389,457 (1,857,939)

Prepaid expenses and other current

assets 539,780 (885,432)

Deposits other than on property

and equipment 304,151 (30,096)

Accounts payable (625,984) 599,249

Accrued expenses and advances (2,260,048) 534,236

Deferred product and contract revenue (189,000) 189,000

Net cash used in operating

activities (35,260,711) (36,331,302)

Cash flows from investing activities:

Purchase of marketable securities (5,867,519) (13,764,736)

Sale and maturities of marketable

securities 6,430,000 24,355,000

Purchases of property and equipment (1,396,954) (300,929)

Deposits on property and equipment - (250,000)

Proceeds from sale of fixed assets - 25,000

Change i
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
2. MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 2008
3. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... July 25, 2014 Sinovac Biotech Ltd. (Nasdaq: ... China , today announced that it will ... June 30, 2014, after market close on Thursday, August 14, ... to the market opening on Friday, August 15, 2014, at ... China Standard Time) to review the Company,s financial results and ...
(Date:7/24/2014)... 24, 2014 -- A novel combination of microscopy and ... Energy,s Oak Ridge National Laboratory an unprecedented look at ... physical and electrochemical properties. , The research team ... the surface of a perovskite manganite, a complex material ... avenue to understand surface behavior could benefit researchers who ...
(Date:7/24/2014)... MESA, Calif. , July 24, 2014  Now ... close to home. Rehealth Regenerative Therapies , located ... athletes and other physically active people a new health ... Regardless of age, countless patients suffer from ... sport activities, such as muscle tears, torn rotator cuff, ...
(Date:7/24/2014)... Calif. , July 24, 2014  ECC West ... Denver, Colorado with University College Hospital (UCH) ... a development project to finance, design, construct, and operate ... Nigeria . Under the first of ... prepare scoping documents and funding applications. UCH Ibadan intends ...
Breaking Biology Technology:Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2ORNL study reveals new characteristics of complex oxide surfaces 2Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
... that want the benefits of cutting-edge health care possibilities ... sub-populations need to foster the new science at ... by Nature Publishing Group. , In a special six-paper ... (NRG), researchers from the McLaughlin-Rotman Centre for Global Health ...
... a significant milestone for the growing open source clincial trials ... towards the needs of regulated industry sponsored clinical trials. ... ... 2008 -- Akaza Research announces the availability of OpenClinica 2.5, ...
... ABBOTT PARK, Ill., Sept. 19 Abbott (NYSE:,ABT) will ... 2008, before the market opens., The announcement will ... call at 8 a.m. Central time (9 a.m. Eastern), ... at, http://www.abbottinvestor.com . An archived edition of the call ...
Cached Biology Technology:As personalized, genomic medicine takes off, four developing countries show the way for others 2As personalized, genomic medicine takes off, four developing countries show the way for others 3As personalized, genomic medicine takes off, four developing countries show the way for others 4As personalized, genomic medicine takes off, four developing countries show the way for others 5As personalized, genomic medicine takes off, four developing countries show the way for others 6As personalized, genomic medicine takes off, four developing countries show the way for others 7Akaza Research Releases New Version of OpenClinica Electronic Data Capture (EDC) Software; Targets Industry Clinical Trials 2Akaza Research Releases New Version of OpenClinica Electronic Data Capture (EDC) Software; Targets Industry Clinical Trials 3
(Date:7/25/2014)... Stowers Institute for Medical Research have identified ... found pheromones crucial to triggering the mating process in ... a male mouse detect pheromones that indicate when a ... him know if the female mouse is ovulating and ... to trigger mating. Stowers, researchers believe mice developed this ...
(Date:7/25/2014)... Florida , July 25, 2014 ... more consumers are turning to digital technology for online ... (OTCBB: NXTD), Google Inc. (NASDAQ: GOOG ), ... (NYSE: V ), Apple Inc. (NASDAQ: ... NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company ...
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
Breaking Biology News(10 mins):It takes two to court 2It takes two to court 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 4Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 5Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 6Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... A research team led by scientists at the Virginia Bioinformatics ... mechanism that allows dangerous fungal microbes to infect plants and ... of new intervention strategies to protect plant, and even some ... in the July 23 edition of the journal Cell ...
... "Many people," says Dr. Eeva Karjalainen, of the Finnish Forest ... out in nature. But not many of us know that ... nature." Forests and other natural, green settings ... and increase overall happiness. Forest visits may also strengthen our ...
... in Chinese . , Formation of new ... sustained tumor growth and cancer metastasis. Recently, clinically available ... been available to improve patient survival in some cancer ... using nonsurgical methods would greatly complement current therapies and ...
Cached Biology News:Scientists discover how deadly fungal microbes enter host cells 2Noninvasive MR imaging of blood vessel growth in tumors using nanosized contrast agents 2Noninvasive MR imaging of blood vessel growth in tumors using nanosized contrast agents 3
... Imaging System, Professional Package Superior Protein ... Range: The ProXPRESS 2D Proteomic Imaging System ... for both proteomic and general life science ... enabling the use of all dyes in ...
... Corning single use spatulas have been ... samples. They are for those interested in ... reusable spatulas. Each spatula is individually packaged, ... CLS number is a new product number, ...
... digital valve, just 8 mm in width. ... in a single glass-reinforced, PBT (Polybutylene Terephthalate) molded ... width. , Meets a range of pressure requirements ... Satisfies a 0.016 sccm leakage specification (0.2 sccm ...
... FilterMate is a compact, versatile system that ... 96- or 24-well microplates into a solid ... liquid scintillation and gamma counter. The FilterMate ... for applications such as cell proliferation, receptor ...
Biology Products: